Sight Sciences Insider Filing: Small Automatic Sale by CTO David Badawi

Rhea-AI Filing Summary

Sight Sciences, Inc. (SGHT) – Form 4 insider transaction

Chief Technology Officer & Director David Badawi disclosed the sale of 5,679 common shares on 03 July 2025 at an average price of $4.174 per share. The disposition was executed to satisfy statutory tax-withholding obligations generated by the vesting of restricted stock units, as noted in the filing’s footnote.

Following the sale, Badawi’s direct beneficial ownership stands at 1,831,025 shares. No derivative securities were reported, and there were no purchases.

The Form 4 indicates an automatic, non-discretionary sale (code “S”) under Rule 16a to cover taxes, which generally carries less negative signaling than voluntary open-market sales. The transaction represents approximately 0.3 % of Badawi’s post-transaction holdings and an immaterial percentage of SGHT’s total shares outstanding.

Positive

• Insider retains a large stake: 1,831,025 shares post-sale, suggesting long-term commitment.

Negative

• Insider sale, even if automatic, can be perceived negatively by some investors.

Insights

Securities Analyst

TL;DR: Small tax-withholding sale; minimal signalling impact.

The 5,679-share sale (~$24k) is routine for RSU tax coverage. Badawi retains 1.83 million shares, indicating continued alignment with shareholders. Given the modest size relative to his stake and SGHT’s float, the filing is not financially material and unlikely to influence valuation or trading sentiment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Badawi David

(Last) (First) (Middle)

C/O SIGHT SCIENCES, INC.

4040 CAMPBELL AVE., SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sight Sciences, Inc. [ SGHT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/03/2025		S		5,679(1)	D	$4.174	1,831,025	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units.

	/s/ Jeremy Hayden, Attorney-in-Fact for David Badawi	07/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Sight Sciences (SGHT) shares did CTO David Badawi sell?

Badawi sold 5,679 common shares on 03 Jul 2025.

What price did the SGHT shares sell for?

The reported average sale price was $4.174 per share.

Why were the SGHT shares sold?

The sale was to cover tax liabilities arising from RSU vesting, per the Form 4 footnote.

How many SGHT shares does Badawi own after the sale?

He directly owns 1,831,025 shares following the transaction.

Is this insider sale considered material to Sight Sciences?

Given the small size (~0.3 % of his holdings), it is not considered material to SGHT’s overall valuation.

Was this sale under a Rule 10b5-1 plan?

The filing does not indicate a Rule 10b5-1 plan checkbox as marked; only an automatic tax-withholding sale is disclosed.